LAMININ RECEPTOR IN BREAST TISSUE, BENIGN AND MALIGNANT TUMORS

乳腺组织、良性和恶性肿瘤中的层粘连蛋白受体

• 批准号: 3963069
• 负责人: G J BRYANT
• 金额: --
• 依托单位: DIVISION OF CANCER BIOLOGY AND DIAGNOSIS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3963069
• 关键词: basement membrane; bladder neoplasm; breast neoplasms; human tissue; metastasis; pancreas neoplasms

Laminin, a major glycoprotein of basement membranes, exhibits saturable binding to the surface of certain neoplastic and normal cells. Examination of various cell types (i.e. human pancreatic carcinoma, melanoma and bladder carcinoma) via live cell binding techniques indicate the number of receptors to be 50-110,000 per cell depending on cell type. In our laboratory, the laminin receptor has been isolated from human breast carcinoma cells and tissue and mouse melanoma cells. The receptor and subsequent ligand binding have been implicated to play an important role in tumor cell attachment, one of the steps in tumor invasion and metastasis. The proposed study is designed to measure and correlate laminin receptor binding capacity of breast tissues with clinical information. Laminin receptor binding capacity markedly differs between benign, malignant and normal human breast tissue. Preliminary studies indicate a 50-fold increase in specific laminin binding activity in malignant versus benign breast tissues. These findings suggest a site for possible intervention in the sequence of tumor invasion.

层粘连蛋白是基底膜的主要糖蛋白，具有饱和性 与某些肿瘤细胞和正常细胞的表面结合。 考试 各种细胞类型（即人类胰腺癌、黑色素瘤和 膀胱癌）通过活细胞结合技术表明 每个细胞有 50-110,000 个受体，具体取决于细胞类型。 在我们的 实验室，层粘连蛋白受体已从人类乳房中分离出来 癌细胞和组织以及小鼠黑色素瘤细胞。 受体和 随后的配体结合被认为在 肿瘤细胞附着，肿瘤侵袭和转移的步骤之一。 拟议的研究旨在测量和关联层粘连蛋白受体 乳腺组织与临床信息的结合能力。 层粘连蛋白 受体结合能力在良性、恶性和 正常人体乳腺组织。 初步研究显示 50 倍 恶性与良性的特异性层粘连蛋白结合活性增加 乳房组织。 这些发现表明了一个可能的干预场所 肿瘤侵袭的顺序。